| Project/Area Number |
17K08375
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
氏家 誠 日本獣医生命科学大学, 獣医学部, 准教授 (50415478)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 抗ウイルス薬 / ウイルス糖タンパク質 / 糖鎖 / 阻害剤 / 抗ウイルス |
|---|
| Outline of Final Research Achievements |
The development of antiviral drugs for emerging and re-emerging viral infections has been greatly delayed. In this study, we aim to identify and develop antiviral drugs that target the virus-specific replication process by host enzymes to avoid the emergence of drug-resistant viruses. We focused on the fact that inhibition of glycan synthesis of viral coat proteins significantly reduces viral infectivity and that glycan synthesis inhibits the maturation of viral particles. We synthesized a fluorescent substrate specific for the glycosidase that works in cultured cells, which will enable us to screen for potential inhibitors of antiviral drugs from a compound library.
|
| Academic Significance and Societal Importance of the Research Achievements |
新興・再興ウイルス感染症に対する抗ウイルス薬の開発は大きく遅れている。抗ウイルス薬はウイルス因子を直接標的とする直接作用抗ウイルス薬（Direct-acting antivirals, DAAs）と宿主因子を標的とする抗ウイルス薬（Host-targeting antivirals, HTAs）に大別される。HTAs は薬剤耐性ウイルスおよび将来的に出現が見込まれる未知のウイルスに効果が期待できる。本研究では HTAs をターゲットとして、社会的要請の高い抗ウイルス薬に関する研究を行った。
|
